에 대한 최신 뉴스 Ramaco Resources (NASDAQ:METC) 주식

Ramaco Resources

Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves and resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mill and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. Operations are concentrated in the Appalachian basin, with active mines at Elk Creek, Berwind, Knox Creek, and Maben mining complexes.

Commodities

METC

RGLD

2024년 5월 9일 주요 뉴스: 피드몬트 리튬(NASDAQ:PLL)은 69%의 기록적인 리튬 회수율을 달성한 노스 아메리칸 리튬(North American Lithium)에서 40,439드라이 메트릭톤(dmt)의 기록적인 생산량을 기록하며 1분기 실적을 보고했다. 

목요일 주요 광업 뉴스: 피드몬트 리튬, 라마코 리소스, 로얄 골드, 트레데거

Ramaco Resources, Inc. - Class A Common Stock

Ramaco Resources Inc

Ramaco Resources, Inc. - Class B Common Stock

Ramaco Resources, Inc. - 9.00% Senior Notes due 2026

Metcash Ltd

Wolfe Research analyst Alexandria Hammond initiates coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform rating and announces Price Target of $190.

News

Price Target

Initiation

Analyst Ratings

Wolfe Research Initiates Coverage On Johnson & Johnson with Outperform Rating, Announces Price Target of $190

Wolfe Research analyst Alexandria Hammond initiates coverage on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform rating and announces Price Target of $110.

GILD

Wolfe Research Initiates Coverage On Gilead Sciences with Outperform Rating, Announces Price Target of $110

General Motors&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) <a href="https://www.benzinga.com/news/24/08/40502871/gms-autonomous-driving-unit-cruise-recalls-all-u-s-vehicles-over-concerns-of-unexpected-braking-auto">autonomous driving unit</a> Cruise has agreed to a payment of $500,000 in criminal fines for providing a false record to the National Highway Traffic Safety Administration (NHTSA) regarding a crash in San Francisco involving one of its autonomous vehicles, the Justice Department said on Thursday.
What Happened: Cruise omitted key details of the accident that occurred in San Francisco on Oct. 2, 2023, in its report to the NHTSA, where a robotaxi ran over a pedestrian who was hit by another vehicle and dragged the woman over 20 feet, the department said. 
Cruise admitted to the allegation and agreed to pay the fine, it added.
"Federal laws and regulations are in place to protect public safety on our roads. &nbsp;Companies with self-driving cars that seek to share our roads and crosswalks must be fully truthful in their reports to their regulators," Martha Boersch, Chief of the Office of the U.S. Attorney's Criminal Division, said in a statement. 
Cruise has also agreed to cooperate with government investigations, implement a Safety Compliance Program, and provide annual reports to the U.S. Attorney's Office for three years, failing which it faces prosecution.
Why It Matters: Cruise suspended all of its operations in the U.S. late last year following the&nbsp;<a href="https://www.benzinga.com/news/23/10/35052444/self-driving-cruise-car-accident-leaves-pedestrian-trapped-and-injured-in-san-francisco" target="_blank" rel="noreferrer noopener">accident in San Francisco</a>, leading to heightened regulatory scrutiny and the&nbsp;<a href="https://www.benzinga.com/news/24/05/38606510/us-is-currently-sc-ed-ex-cruise-ceo-calls-for-manufacturing-makeover-to-win-over-chinese-auto-rivals" target="_blank" rel="noreferrer noopener">exit of its co-founder&nbsp;</a>and then CEO&nbsp;Kyle Vogt.
The company&nbsp;<a href="https://www.benzinga.com/news/24/04/38155753/cruise-back-on-phoenix-roads-soon-gms-self-driving-unit-reportedly-gears-up-to-resume-robotaxi-testi" target="_blank" rel="noreferrer noopener">resumed manual driving in the city of Phoenix</a>&nbsp;to gather road information earlier this year in April and in Houston and Dallas, Texas in June.
Cruise&nbsp;is now looking to return to operating driverless vehicles by the end of the year, GM CEO&nbsp;Mary Barra&nbsp;said during the company&#8217;s&nbsp;<a href="https://www.benzinga.com/news/earnings/24/10/41451103/general-motors-surpasses-q3-earnings-and-revenue-estimates" target="_blank" rel="noreferrer noopener">third-quarter earnings call</a> last month.
Cruise&#8217;s Financials: Cruise posted an operating loss of $417 million in the three months through the end of September, lower than the $807 million loss recorded in the corresponding period of last year. GM has spent $583 million on restructuring Cruise this year.
In July, the company also said that it is abandoning its plans to build the Origin autonomous vehicle with no pedals and instead focussing on&nbsp;<a href="https://www.benzinga.com/news/24/07/39903020/gms-cruise-abandons-pedal-less-origin-autonomous-vehicle-pivots-to-next-generation-chevrolet-bolt-in" target="_blank" rel="noreferrer noopener">using its next-generation Chevrolet Bolt&nbsp;</a>for autonomous driving operations.
"This addresses the regulatory uncertainty we faced with the Origin because of its unique design. In addition, per-unit costs will be much lower, which will help Cruise optimize its resources,&#8221; Barra said about the decision then.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42000554/spacex-speeds-up-mission-launches-with-a-new-one-taking-off-every-other-day-over-last-month-as-it-races-towards-its-2024-target">SpaceX Speeds Up Mission Launches With A New One Taking Off Every Other Day Over Last Month As It Races Towards Its 2024 Target</a></li>
</ul>
Photo courtesy: GM

Tech

GM's Autonomous Driving Unit Cruise Admits To Falsifying Accident Report To NHTSA, Agrees To Pay $500K Fine

Wolfe Research analyst Alexandria Hammond initiates coverage on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Bristol-Myers Squibb with Peer Perform Rating

Wolfe Research analyst Tim Anderson initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Peer Perform rating.

AMGN

Wolfe Research Initiates Coverage On Amgen with Peer Perform Rating

Wolfe Research analyst Akash Tewari initiates coverage on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform rating and announces Price Target of $95.

BMRN

Wolfe Research Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $95

Wolfe Research analyst Alexandria Hammond initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Peer Perform rating.

BIIB

Wolfe Research Initiates Coverage On Biogen with Peer Perform Rating

Wolfe Research analyst Alexandria Hammond initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform rating and announces Price Target of $205.

ABBV

Wolfe Research Initiates Coverage On AbbVie with Outperform Rating, Announces Price Target of $205

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Reiteration

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $23 price target.

CELC

Needham Reiterates Buy on Celcuity, Maintains $23 Price Target

Needham analyst Ryan Koontz reiterates Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) with a Buy and maintains $8.5 price target.

GILT

Needham Reiterates Buy on Gilat Satellite Networks, Maintains $8.5 Price Target

<ul>
<li>Aegon today announces a planned new EUR 150 million share buyback program, consistent with its policy to return excess Cash Capital at Holding to shareholders in the absence of value-creating opportunities. Barring unforeseen circumstances, the share buyback program will start at the beginning of January 2025 and is expected to be completed on or before June 30, 2025. The start of this share buyback program will be announced separately in due course.&nbsp;</li>
<li>The new planned EUR 150 million share buyback program will include an amount of about EUR 40 million to meet Aegon's obligations resulting from the share-based compensation plans for senior management. The repurchased shares resulting from these compensation plans will be held as treasury shares until they are allocated to the plan participants. Aegon intends to cancel the remainder of the repurchased shares resulting from the new planned share buyback program, subject to any relevant approval.</li>
</ul>

Aegon Announces €150M Share Buyback Starting January 2025, With €40M For Compensation And The Rest For Cancellation, Pending Approval

Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has filed a lawsuit against the Health Resources and Services Administration (HRSA). The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.
What Happened: As per Eli Lilly&#8217;s official statement on Thursday, the conflict centers on the federal 340B program, which requires drug manufacturers to offer discounts to healthcare providers serving low-income communities. Participation in this program is crucial for drug companies to secure funding from government health insurance programs like Medicare and Medicaid.
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. However, HRSA, a division of the U.S. Health and Human Services Department, rejected this approach, stating it was inconsistent with the 340B law.
&#8220;HRSA does not have the authority to arbitrarily reject this model, which serves the original goals of the 340B program and improves transparency, efficiency, and program integrity,&#8221; the statement read.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Why It Matters: The lawsuit comes amid ongoing scrutiny of drug pricing practices. Recently, <a href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price">Doctors Without Borders</a> criticized Eli Lilly and other insulin manufacturers for maintaining high prices, urging them to provide affordable insulin to low- and middle-income countries.
This legal action also <a href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs">follows a similar lawsuit</a> by Johnson &amp; Johnson, which alleged the Health and Human Services Department of blocking its drug rebate plans. The 340B program has been subject to extensive legal challenges, with a U.S. appeals court previously allowing drugmakers to limit the use of outside pharmacies for dispensing under the program.
Meanwhile, Eli Lilly has been in the spotlight for its <a href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years">Phase 3 trial data</a> of tirzepatide, marketed as Mounjaro and Zepbound. The study showed promising results in reducing the risk of type 2 diabetes in patients with pre-diabetes and obesity, highlighting the company&#8217;s focus on innovative treatments.
Price Action: Eli Lilly was down by 0.28% during pre-market hours on Friday at the time of writing, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41921267/new-jersey-is-making-history-by-offering-medical-cannabis-as-employee-benefit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">New Jersey Is Making History By Offering Medical Cannabis</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Biotech

Government

Health Care

General

Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program

Needham analyst James Ricchiuti reiterates 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) with a Hold.

Needham Reiterates Hold on 3D Sys

Aegon trading update for third quarter 2024&nbsp;
• EUR 336 million operating capital generation, before holding funding and operating expenses. Full-year 2024 guidance raised to around EUR 1.2 billion, from around EUR 1.1 billion previously&nbsp;
• Capital ratios of the main units remain above their respective operating levels&nbsp;
• Planned new EUR 150 million share buyback program announced; completion expected in the first half of 2025. The program includes neutralization of shares issued for share-based compensation plans&nbsp;
• Cash Capital at Holding of EUR 1.5 billion as of September 30, 2024. Expect to reach mid-point of the target range (EUR 1.0 billion) by the end of 2026&nbsp;
• Completed program to purchase institutionally owned universal life policies. Terminated policies negatively impacted US RBC ratio by 16%-points. Expect 8%-points benefit in 4Q 2024 after equity funding repayment. Operating capital generation benefits from the program, as previously guided&nbsp;
• Strong commercial momentum in Asset Management and UK Workplace platform. US Strategic Assets experience c

Aegon Q3 Business Update: Operating Capital Generation €336M Before Holding Expenses; Raised FY24 Operating Capital Target To ~€1.2B, Up From The Previous Estimate Of €1.1B

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Buy and maintains $9 price target.

INKT

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) with a Neutral.

STTK

HC Wainwright & Co. Reiterates Neutral on Shattuck Labs

Macro Economic Events

Econ #s

Economics

U.K. Labour Productivity For Q2 0.2% Vs. 0.1% Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $14 price target.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $14 Price Target

In a report released today, Nathan Martin from Benchmark Co. assigned a Buy rating to Ramaco Resources (METC – Research Report), with a price targe...

Benchmark Co. Gives a Buy Rating to Ramaco Resources (METC)

BofA latest to cut oil price view on weak demand, limiting OPEC's ability to boost output

Warning: METC is at high risk of performing badly

METCB May Be Yielding Over 12% In 2025 At A Sub $10 Stock Price

Ramaco Q3 2024 Earnings Preview

Here are the major earnings after the close today

Ramaco Non-GAAP EPS of $0.00 misses by $0.04, revenue of $167.4M beats by $10.99M

Ramaco Resources ( ($METC) ) has issued an update. Ramaco Resources reported strong operational performance in the third quarter of 2024, despite a...

Ramaco Resources Achieves Record Production Amid Market Challenges

Ramaco Resources, Inc. (METC) Q3 2024 Earnings Call Transcript

Ramaco Resources ( ($METC) ) has released its Q3 earnings. Here is a breakdown of the information Ramaco Resources presented to its investors. Rama...

Ramaco Resources Faces Challenges Amid Operational Gains

ABCL

ALAB

ANDE

AOSL

APLE

AQST

ATUS

AZPN

BATL

BCOV

BOIL

BWXT

CDNA

CENX

CLLS

CRGY

CRUS

CSTL

DRIP

EGHT

EOSE

GUSH

HDSN

HIMS

HNRG

HOLX

ICHR

ILMN

INDO

INSP

ITUB

KLXE

KOLD

LSCC

METCB

METCL

NTST

NVTS

OTTR

PARR

SGML

USOI

VTLE

WLKP

Press Releases

Ramaco Announces Hiring of Two Vice Presidents

Earnings

RAMACO RESOURCES REPORTS FIRST QUARTER 2024 RESULTS

Ramaco Announces New Leadership Structure to Accelerate Growth

Global Researchers, National Political Leaders Convene for Leading Wyoming Research Conference

Ramaco Resources, Inc. to Release Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 and Host Conference Call and Webcast on Thursday, August 8, 2024

Ramaco Announces Project Update and New Third-Party Groups Assisting in Development of Rare Earth Elements Deposit at Brook Mine

RAMACO RESOURCES REPORTS SECOND QUARTER 2024 RESULTS

Ramaco Hires Senior Vice President of Technology from DARPA to Support Rare Earth Element and Carbon Product Development

Ramaco Resources, Inc. to Release Third Quarter 2024 Financial Results on Monday, November 4, 2024 and Host Conference Call and Webcast on Tuesday, November 5, 2024

RAMACO RESOURCES REPORTS THIRD QUARTER 2024 RESULTS

Alpha Metallurgical Resources, Inc. Common Stock

Alpha Metallurgical

Cleveland-Cliffs

Commercial Metals

Carpenter Technology Corporation Common Stock

Carpenter Tech

Gerdau

Haynes International, Inc. - Common Stock

Haynes Intl

Warrior Met Coal

ArcelorMittal

Metallus

Nucor

POSCO HOLDINGS INC. American Depositary Shares (Each representing 1/4th of a share of Common Stock)

POSCO Holdings

Radius Recycling, Inc. - Class A Common Stock

Radius Recycling

Reliance

Ryerson Holding

Companhia Siderurgica Nacional S.A. Common Stock

Companhia Siderurgica

Grupo Simec, S.A.B. de C.V. American Depositary Shares

Grupo Simec

Steel Dynamics

SunCoke Energy

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium

VALE S.A. American Depositary Shares Each Representing one common share

Vale

Worthington Steel

United States Steel Corporation Common Stock

United States Steel

Olympic Steel

B. Riley Securities

Benchmark

BMO Capital

Jefferies

<h3 class="wp-block-heading">2024년 5월 9일 주요 뉴스:</h3>
<ol>
<li>피드몬트 리튬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>)은 69%의 기록적인 리튬 회수율을 달성한 노스 아메리칸 리튬(North American Lithium)에서 40,439드라이 메트릭톤(dmt)의 기록적인 생산량을 기록하며 <a href="https://www.benzinga.com/news/earnings/24/05/38727020/piedmont-lithium-q1-2024-adj-eps-0-61-misses-0-54-estimate-sales-13-400m-miss-15-367m-estimate">1분기 실적</a>을 보고했다.</li>
</ol>
이 회사는 하반기에 최대 가동률 생산을 기대하고 있으며, 주로 하반기에 연간 약 126,000dmt를 출하할 계획이다.
2024년 3월 31일 기준 스포듀민 정광(spodumene concentrate) 15,500dmt의 판매로 매출은 1,340만 달러에 달했으며, 현금 보유액은 7,140만 달러에 달했다.
피드몬트는 2024년 하반기에 출하량은 두 배로, 투자 비용은 절반으로 줄일 것으로 예상하고 있다.
캐롤라이나 리튬에 대한 채굴 허가도 2024년 5월에 발행되어 자금 조달 논의가 활발해졌다.
<ol start="2">
<li>라마코 리소스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>)는 1분기 순이익 200만 달러, 조정 EBITDA 2,420만 달러를 보고했는데, 이는 둘 다 2023년 4분기보다 크게 감소한 수치이다.</li>
</ol>
어려운 지질학적 문제와 노동 문제로 인해 석탄 가격이 낮아지고 채굴 비용이 높아지면서 결과에 영향을 미쳤다.
이 회사는 3월에 대부분의 수출품을 저렴한 가격으로 선적했으며 신용 시설을 2억 달러로 늘렸으며 옵션을 2억 7,500만 달러까지 늘릴 수 있었다.
라마코는 또한 2024년 6월에 지급할클래스 A와 B 주식의 분기 배당금도 선언했다.
또 읽기: <a href="https://www.benzinga.com/news/24/05/38703659/de-grey-mining-plans-to-raise-395m-for-major-gold-project-in-australia" target="_blank" rel="noopener">드 그레이 마이닝</a><a href="https://www.benzinga.com/news/24/05/38703659/de-grey-mining-plans-to-raise-395m-for-major-gold-project-in-australia">, 호주의 주요 금 프로젝트를 위해 3억 9500만 달러 조달할 계획</a>
<ol start="3">
<li>로얄 골드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLD#NASDAQ">RGLD</a>)는 1분기 순이익은 4,720만 달러, 매출 1억 4,890만 달러, 영업현금흐름은 1억 3,830만 달러를 기록했다.</li>
</ol>
이 회사는 이번 분기에 1억 달러의 부채를 상환하고, 총 부채를 1억 5천만 달러로 줄였으며, 유동성을 9억 6,600만 달러로 늘렸다.
매출은 주로 금(75%)에서 발생했으며, 은(13%), 구리(9%)가 그 뒤를 이었다. 이 회사는 71,900 금 상당 온스를 판매했으며 79%의 높은 조정 EBITDA 마진을 유지했다.
분기별 배당금은 주당 40센트로 7% 증가했으며, 분기 이후 회사는 추가로 7,500만 달러의 부채를 상환하여 총 부채를 7,500만 달러로 줄였다.
<ol start="4">
<li>트레데거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TG#NYSE">TG</a>)는 1분기 순이익은 330만 달러로 2023년 1분기 손실 100만 달러에서 상승했다.</li>
</ol>
알루미늄 압출 부문의 EBITDA는 전년 동기 대비 1,460만 달러에서 1,250만 달러로 감소한 반면, PE 필름의 EBITDA는 180만 달러에서 690만 달러로 증가했다.
부문별 판매량은 엇갈린 결과를 보였으며, 2023년 1분기에 비해 순 신규 주문은 61% 증가했다.
이 회사는 터패인(Terphane)이라는 유연한 포장 필름 사업 부문을 매각하는 과정에 있다.
지금 읽기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38731223/barrick-gold-ceo-says-mergers-wont-fix-the-copper-shortage">배릭 골드 CEO, 합병도 구리 부족 문제를 해결 못 한다고 말해</a>
Benzinga Mining은 광산 기업과 소매 투자자 사이의 연결다리입니다. Benzinga 커뮤니티와 연결하려면 <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a>으로 연락해주세요!
사진: 셔터스톡

Comments

Ramaco Resources

뉴스

에 대한 최신 뉴스 Ramaco Resources (NASDAQ:METC) 주식

금요일, 5월 10, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌